Epigenetics Industry worth $4.3 billion by 2028, with a CAGR of 18.3%
The report "Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method (DNA Methylation), Technique (NGS, PCR, Mass Spectrometry), Application (Oncology, Immunology) - Global Forecast to 2028 ", is projected to reach USD 4.3 billion by 2028 from USD 1.8 billion in 2023, at a CAGR of 18.3% during the forecast period of 2023 to 2028.
Browse 367 market data Tables and 45 Figures spread through 366 Pages and in-depth TOC on "Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method (DNA Methylation), Technique (NGS, PCR, Mass Spectrometry), Application (Oncology, Immunology) - Global Forecast to 2028 "
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/epigenetics-technologies-market-896.html
The global epigenetics market is expected to grow at a CAGR of 18.3 % during the forecast period. The growth of the market is projected to be driven by factors such as as rising investment in R&D, declining sequencing cost & time, favorable government initiatives & funding for epigenetics research, advancement in technology for epigenetic research and increasing demand for epigenetic-based therapeutics.
The kits & reagents segment segment is expected to have the dominant share of the epigenetics market in 2022.
Based on technology, the global epigenetics market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service. The kits & reagents is further segmented into antibodies, chip-sequencing kits & reagents, whole-genome amplification kits & reagents and 5-HMC & 5-MC Analysis kits & reagents, histones and other kits & reagents. In 2022, the Antibodies segment held the largest share of the epigenetics market. The rising adoption of antibodies in detection, identification, and alteration/modification of proteins followed by their role in monitoring cell regulation & expression are the driving factor for the growth of the antibodies segment during the forecast period.
The DNA methylation segment accounted for the largest share of the method segment in the epigenetics market in 2022.
Based on disease indication, the epigenetics market is segmented DNA methylation, histone modifications, and other methods (non-coding RNA and chromatin remodelling). The DNA methylation segment is anticipated to grow at significant CAGR during the forecast period owing to factor such as efficacy of the DNA methylation technique in oncology studies.
The Asia Pacific region is the fastest-growing region of the epigenetics market in 2022.
The Asia Pacific is accounted to be the fastest-growing segment of the market. The growth of the epigenetics markets in the region is driven by the expanding international presence of domestic players by adopting strategic agreements, partnerships, and collaborations and Improving healthcare infrastructure in developing Asia Pacific economies.
Key Players
The epigenetics market is moderately consolidated, with a small number of players competing for market shares. Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Abcam plc (UK), Active Motif, Inc. (US), Bio-Rad Laboratories Inc. (US), Promega Corporation (US), Revvity (US), Qiagen (Germany), New England Biolabs (US), Zymo Research Corporation (US), Diagenode SA (US), F. Hoffmann-La Roche Ltd (Switzerland) and Epigentek Group Inc. (US) are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, and agreements, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Epigenetics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
